Neuralstem in the News
“After Successful ALS Phase I, Neuralstem Branches Out”
A one-time broker cites the recent licensing agreement with Cedars-Sinai Medical Center, enabling neural stem cell research at the prestigious institution, and explores the factors leading up to it.
“Scientists Seek Stem Cell Cure For Spinal Cord Injuries”
Feature reporter Emily B. Berman steps inside Neuralstem’s main lab and headquarters’ office for a first-hand, comprehensive look at the science and the promise of Neuralstem on the heels of FDA approval of cSCI trial.
“ALS Patient Is Living His Second Miracle: Follow-up stem-cell operation has more amazing results”
November 30, 2012
“We’ve got to turn Lou Gehrig’s disease into Lou Gehrig’s chronic illness,” Ted Harada says three months following his impactful second treatment in Neuralstem’s ALS Phase I trial. In this follow-up interview, Ted reports that there’s a spring in his step – along with increased strength, a strong grip, and ALS symptoms again “in retreat.”
“Can Patients Scoop Clinical Trial Results?”
An ex-scientist and professional investor and analyst shares insights on, and examples of, smart online and social media “detective work,” to gain additional intelligence when investing in biotech.
“Neuralstem Overview Article by Larry Smith”
Former long-standing biotech and pharmaceuticals analyst and former Director of Research at Smith Barney and Hambrecht & Quist, provides an in-depth overview of the industry, and Neuralstem’s progress and outlook in both its stem cell therapy and neurogenic pharmaceutical divisions.
- Stem cell therapy helps paraplegic rats regain movement
- Paralyzed Rats Walk Again After Stem Cell Transplant: The rodent recovery spurs hope that humans could one day benefit from similar treatments.
- Neuralstem Gains on Stem Cell Therapy for Paralyzed Rats
- Stem Cells Help Rats Recover Lower-Body Movement
- Neuralstem Overview Article
Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.